WO2007144323A2 - Solid forms containing meloxicam with improved taste and process for their preparation - Google Patents

Solid forms containing meloxicam with improved taste and process for their preparation Download PDF

Info

Publication number
WO2007144323A2
WO2007144323A2 PCT/EP2007/055706 EP2007055706W WO2007144323A2 WO 2007144323 A2 WO2007144323 A2 WO 2007144323A2 EP 2007055706 W EP2007055706 W EP 2007055706W WO 2007144323 A2 WO2007144323 A2 WO 2007144323A2
Authority
WO
WIPO (PCT)
Prior art keywords
solid dosage
meloxicam
dosage form
acid
polyalcohols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/055706
Other languages
French (fr)
Other versions
WO2007144323A3 (en
Inventor
Federico Stroppolo
Shahbaz Ardalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpex Pharma SA
Original Assignee
Alpex Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpex Pharma SA filed Critical Alpex Pharma SA
Priority to EP07730048.1A priority Critical patent/EP2046337B1/en
Priority to US12/299,838 priority patent/US10016359B2/en
Priority to PL07730048T priority patent/PL2046337T3/en
Publication of WO2007144323A2 publication Critical patent/WO2007144323A2/en
Publication of WO2007144323A3 publication Critical patent/WO2007144323A3/en
Anticipated expiration legal-status Critical
Priority to CY20171100821T priority patent/CY1119315T1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the invention refers to solid forms containing meloxicam with improved buccal taste and to a method to improve taste of the non steroidal anti-inflammatory drug meloxicam starting from a solid dosage form for buccal administration.
  • the method consists in the use of a micronised form of meloxicam formulated in presence of an edible acid and a sugar or a polyalcohol.
  • Oral suspensions could solve the administration problem but present some drawbacks due to the weight of the container, usually consisting of glass and subsequent lack of comfort, e.g. when the patient travels.
  • Meloxicam a known non steroidal anti-inflammatory drug (NSAID) is marketed by Boehringer-Ingelheim in the form of tablets, oral suspensions and suppositories.
  • Meloxicam as most drugs belonging to the category of oxicams such as am- piroxicam, droxicam and piroxicam, is characterized by a bitter taste making difficult its buccal administration in form of oral disintegrating tablet.
  • CN1546033 (Chengu Shengnuo Sci. & Technology Dev. Gb.) discloses ODT of meloxicam containing lactose, mannitol, crystalline cellulose, low substituted methyl- cellulose, propylene glycol ether, cross bonding polyvinylpyrrolidone, sodium hydrogen carbonate, citric acid, aspartame, perfume and magnesium stearate.
  • WO 2005/117895 (Boehringer Ingelheim) discloses solid dosage forms containing meloxicam in combination with another active ingredient in admixture with a pharmaceutically acceptable carrier.
  • WO 99/09988 discloses solid dosage forms of meloxicam with improved solubility and bioavailability.
  • the quantity of acid required in the formulation ranges from 0.1% to 900% by weight of meloxicam, preferably from 0.3% to 500% by weight of meloxicam and most preferably between 0.5% to 100% by weight of meloxicam. Particularly preferred amounts of acids range from 0.8% to 1.5% by weight of meloxicam.
  • the quantitative ratio of the poly alcohol mixture to meloxicam ranges from 1 : 1 to 1:100, most preferably from 1 to 10.
  • the ratio between the polyalcohol having a negative temperature of dissolution versus the other polyalcohol(s) ranges from 0.1 :50, preferably 0.5:50, most preferably 0.9:1.5.
  • the quantity of meloxicam is typically in the range of 0.5 to 30 mg per dose.
  • acids for use according to the invention include citric, tartaric, malic, gluconic acids, etc. Citric acid and tartaric acid are preferred.
  • sugar examples include glucose, fructose, lactose, maltose, idose, sucrose, mannose, gulose, talose, maltol, ribose, arabinose, xilose, lyxose, etc or mixture thereof.
  • polyalcohols examples include xylitol, mannitol, sorbitol, idole, etc.
  • Polyalcohols or sugars having a negative temperature of dissolution includes sorbitol, xylytol, maltol, maltitol, etc. These compounds when dissolved in water decrease the temperature of the generated solution.
  • the tablets of the invention could be obtained by a process including direct blending, wet granulation or fluid-bed granulation.
  • Oral dispersible tablets containing 15 mg of meloxicam were prepared as follows: [0028] Polyvinylpyrrolidone (Kollidon®) (10 g) were dissolved in purified water (about 30 g)- [0029] Meloxicam (37.5 g), mannitol (560 g), sorbitol (277.5 g), citric acid (37.5 g), aspartame (20.0 g) and Kollidon® (20 g) were sieved and loaded in a fluid bed granulator Strea 1.
  • the powder was granulated with the above aqueous solution of Kollidon®. [0031] The granular was then dried until a moisture not higher than 0.5% and cooled to room temperature. [0032] The granular was then blended until homogeneity in a cube mixer with of flavour
  • Example 2 Preparation of an oral dispersible tablet containing 7.5 mg of meloxicam.
  • Oral dispersible tablets containing 7.5 mg of meloxicam were prepared as follows. [0036] A granular was prepared as described in the example 1. [0037] The blended product was compressed in round shaped tablets with a diameter of 9.0 mm, weighing 200 mg and containing 7.5 mg of meloxicam. [0038] Comparative Example 3
  • Kollidon® (10 g) were dissolved in purified water (about 30 g).
  • Meloxicam (37.5 g), citric acid (875 g), aspartame (20.0 g) and Kollidon® (20 g) were sieved and loaded in a fluid bed granulator Strea 1 ;
  • the powder was granulated with the above aqueous solution of Kollidon®. [0049] The granular was then dried until a moisture limit of not more than 0.5% and cooled to room temperature.
  • Example 5 The taste of tablets manufactured according the examples 1 to 4 has been evaluated by administering the tablets to a group of 28 volunteers. The taste evaluation is reported below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A solid dosage form of meloxicam containing an acid and sugars or polyalcohols or a mixture thereof.

Description

Description
SOLID FORMS CONTAINING MELOXICAM WITH IMPROVED BUCCAL TASTE AND PROCESS FOR THEIR PREPARATION
[0001] The invention refers to solid forms containing meloxicam with improved buccal taste and to a method to improve taste of the non steroidal anti-inflammatory drug meloxicam starting from a solid dosage form for buccal administration.
[0002] The method consists in the use of a micronised form of meloxicam formulated in presence of an edible acid and a sugar or a polyalcohol.
[0003] Background of the invention
[0004] Swelling of solid dosage forms such as tablets (regular, film- or sugar-coated) and capsules (soft and hard), represent a problem causing difficult in ingestion for a significant portion of the adult population (about 30%). The incidence of these difficulties significantly increases in children and teenagers and in the elderly population in view of difficulty in ingestion.
[0005] Oral suspensions could solve the administration problem but present some drawbacks due to the weight of the container, usually consisting of glass and subsequent lack of comfort, e.g. when the patient travels.
[0006] For this reason, solid formulations which readily dissolve when administered are preferred.
[0007] Unfortunately not all active components can be formulated in oral disintegrating tablet (ODT) form, because of taste or stability problems.
[0008] In particular, when ODT dissolves into the oral cavity, the concentration of drug in the saliva is very high, due to the reduced volume of saliva (0.5-1.0 ml) causing taste problems.
[0009] Meloxicam, a known non steroidal anti-inflammatory drug (NSAID), is marketed by Boehringer-Ingelheim in the form of tablets, oral suspensions and suppositories.
[0010] Meloxicam, as most drugs belonging to the category of oxicams such as am- piroxicam, droxicam and piroxicam, is characterized by a bitter taste making difficult its buccal administration in form of oral disintegrating tablet.
[0011] CN1546033 (Chengu Shengnuo Sci. & Technology Dev. Gb.) discloses ODT of meloxicam containing lactose, mannitol, crystalline cellulose, low substituted methyl- cellulose, propylene glycol ether, cross bonding polyvinylpyrrolidone, sodium hydrogen carbonate, citric acid, aspartame, perfume and magnesium stearate. [0012] WO 2005/117895 (Boehringer Ingelheim) discloses solid dosage forms containing meloxicam in combination with another active ingredient in admixture with a pharmaceutically acceptable carrier.
[0013] WO 99/09988 (Hexal AG) discloses solid dosage forms of meloxicam with improved solubility and bioavailability.
[0014] Description of the invention
[0015] Surprisingly, it has been found that by addition of an acid to a buccal formulation together with a mixture of poly alcohols, at least one of which having preferably a negative temperature of dissolution, the taste of the drug is greatly improved, allowing the oral administration of the drug in solid form, without any inconvenience for the patient.
[0016] The quantity of acid required in the formulation ranges from 0.1% to 900% by weight of meloxicam, preferably from 0.3% to 500% by weight of meloxicam and most preferably between 0.5% to 100% by weight of meloxicam. Particularly preferred amounts of acids range from 0.8% to 1.5% by weight of meloxicam.
[0017] The quantitative ratio of the poly alcohol mixture to meloxicam ranges from 1 : 1 to 1:100, most preferably from 1 to 10. The ratio between the polyalcohol having a negative temperature of dissolution versus the other polyalcohol(s) ranges from 0.1 :50, preferably 0.5:50, most preferably 0.9:1.5.
[0018] The quantity of meloxicam is typically in the range of 0.5 to 30 mg per dose.
[0019] Examples of acids for use according to the invention include citric, tartaric, malic, gluconic acids, etc. Citric acid and tartaric acid are preferred.
[0020] Examples of sugar include glucose, fructose, lactose, maltose, idose, sucrose, mannose, gulose, talose, maltol, ribose, arabinose, xilose, lyxose, etc or mixture thereof.
[0021] Examples of polyalcohols include xylitol, mannitol, sorbitol, idole, etc.
[0022] Polyalcohols or sugars having a negative temperature of dissolution includes sorbitol, xylytol, maltol, maltitol, etc. These compounds when dissolved in water decrease the temperature of the generated solution.
[0023] The tablets of the invention could be obtained by a process including direct blending, wet granulation or fluid-bed granulation.
[0024] In case of fluid bed granulation the sieved powder of meloxicam, polyalcohols, acid, and other excipients such as sweetening agents, are granulated with a water solution containing a binder, such as polyvinylpyrrolidone, PEG, sodium carboxymethyl cellulose etc followed by drying, blending of the granular with lubricants (e.g. magnesium stearate) and final tabletting. [0025] The invention is illustrated by the following examples. [0026] Example 1 - Preparation of an oral dispersible tablet containing 15 mg of meloxicam.
[0027] Oral dispersible tablets containing 15 mg of meloxicam were prepared as follows: [0028] Polyvinylpyrrolidone (Kollidon®) (10 g) were dissolved in purified water (about 30 g)- [0029] Meloxicam (37.5 g), mannitol (560 g), sorbitol (277.5 g), citric acid (37.5 g), aspartame (20.0 g) and Kollidon® (20 g) were sieved and loaded in a fluid bed granulator Strea 1.
[0030] The powder was granulated with the above aqueous solution of Kollidon®. [0031] The granular was then dried until a moisture not higher than 0.5% and cooled to room temperature. [0032] The granular was then blended until homogeneity in a cube mixer with of flavour
(25 g) and of magnesium stearate (12.5 g). [0033] The blended product was then compressed in round shaped tabletd with a diameter of 12 mm, weighing 400 mg and containing 15 mg of meloxicam. [0034] Example 2 - Preparation of an oral dispersible tablet containing 7.5 mg of meloxicam.
[0035] Oral dispersible tablets containing 7.5 mg of meloxicam were prepared as follows. [0036] A granular was prepared as described in the example 1. [0037] The blended product was compressed in round shaped tablets with a diameter of 9.0 mm, weighing 200 mg and containing 7.5 mg of meloxicam. [0038] Comparative Example 3
[0039] Kollidon® (10 g) were dissolved in purified water (about 30 g). [0040] Meloxicam (37.5 g), citric acid (875 g), aspartame (20.0 g) and Kollidon® (20 g) were sieved and loaded in a fluid bed granulator Strea 1 ;
[0041] The powder was granulated with the above aqueous solution of Kollidon®. [0042] The granular was then dried until a moisture not higher than 0.5% and cooled to room temperature. [0043] The granular was then blended until homogeneity in a cube mixer with flavour (25 g) and magnesium stearate (12.5 g). [0044] The blended product was then compressed in round shaped tablets with a diameter of 12 mm, weighing 400 mg and containing 15 mg of meloxicam. [0045] Comparative Example 4 [0046] Kollidon® (10 g) were dissolved in purified water (about 30 g). [0047] Meloxicam (37.5 g), mannitol (585 g), sorbitol (290 g), aspartame (20.0 g) and Kollidon® (20 g) were sieved and loaded in a fluid bed granulator Strea 1.
[0048] The powder was granulated with the above aqueous solution of Kollidon®. [0049] The granular was then dried until a moisture limit of not more than 0.5% and cooled to room temperature.
[0050] The granular was then blended until homogeneity in a cube mixer with flavour (25 g) and magnesium stearate (12.5 g). [0051] The blended product was then compressed in round shaped tablets with a diameter of 12 mm, weighing 400 mg and containing 15 mg of meloxicam.
[0052] Example 5 [0053] The taste of tablets manufactured according the examples 1 to 4 has been evaluated by administering the tablets to a group of 28 volunteers. The taste evaluation is reported below:
[0054]
[Table 0001] [Table ] Table 1
Figure imgf000005_0001
[0055]

Claims

Claims
[0001] A solid dosage from of meloxicam containing an acid and sugars or poly alcohols or a mixture thereof characterized in that at least one sugar or one polyalcohol has a negative temperature of dissolution.
[0002] A solid dosage form according to claim 1 in the form of buccal tablets.
[0003] A solid dosage form according to claim 1 wherein the acid is citric acid or tartaric acid.
[0004] A solid dosage form according to claim 1 wherein the sugar or polyalcohols are glucose, fructose, lactose, maltose, idose, sucrose, mannose, gulose, talose, maltol, ribose, arabinose, xilose, lyxose, xylitol, mannitol, sorbitol, idole or mixtures thereof.
[0005] A solid dosage form according to claim 1 wherein the sugars or polyalcohols having a negative dissolution temperature are sorbitol, xylytol, maltol, maltitol or mixtures thereof.
[0006] A solid dosage form according to claim 1 wherein the mixture of polyalcohols comprises mannitol and sorbitol.
[0007] A process for the preparation of a solid dosage form according to claim 1 including the direct blending of a sieved powder of meloxicam, polyalcohols, acid, optional other excipients and blending with lubricants and optionally with other excipients and tabletting the blended granulate.
[0008] A process for the preparation of a solid dosage form according to claim 1 including the wet granulation of a sieved powder of meloxicam, polyalcohols, acid, optional other excipients and optionally a binder with a water solution of a binder, followed by drying, blending the cooled granulate with lubricants and optionally with other excipients and tabletting the blended granulate.
[0009] A process for the preparation of a solid dosage form of claim 1 including the fluid-bed granulation of a sieved powder of meloxicam, polyalcohols, acid, optional other excipients and optionally a binder with a water solution of a binder, followed by drying, blending the cooled granulate with lubricants and optionally with other excipients and tabletting the blended granulate.
[0010] The use of an edible acid and a mixture of polyalcohols, at least one of which having a negative temperature of dissolution, for the preparation of a taste- masked solid dosage form of meloxicam.
PCT/EP2007/055706 2006-06-15 2007-06-11 Solid forms containing meloxicam with improved taste and process for their preparation Ceased WO2007144323A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07730048.1A EP2046337B1 (en) 2006-06-15 2007-06-11 Solid forms containing meloxicam with improved buccal taste and process for their preparation
US12/299,838 US10016359B2 (en) 2006-06-15 2007-06-11 Solid forms containing meloxicam with improved buccal taste and process for their preparation
PL07730048T PL2046337T3 (en) 2006-06-15 2007-06-11 Solid forms containing meloxicam with improved buccal taste and process for their preparation
CY20171100821T CY1119315T1 (en) 2006-06-15 2017-07-31 SOLID FORMS CONTAINING MELOXICAM WITH IMPROVED ORAL TASTE AND THE PROCEDURE FOR THEIR PREPARATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012353.6 2006-06-15
EP06012353A EP1870102A1 (en) 2006-06-15 2006-06-15 Solid forms containing meloxicam with improved taste and process for their preparation

Publications (2)

Publication Number Publication Date
WO2007144323A2 true WO2007144323A2 (en) 2007-12-21
WO2007144323A3 WO2007144323A3 (en) 2008-03-13

Family

ID=37188954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/055706 Ceased WO2007144323A2 (en) 2006-06-15 2007-06-11 Solid forms containing meloxicam with improved taste and process for their preparation

Country Status (7)

Country Link
US (1) US10016359B2 (en)
EP (2) EP1870102A1 (en)
CY (1) CY1119315T1 (en)
HU (1) HUE034161T2 (en)
PL (1) PL2046337T3 (en)
TW (1) TW200815015A (en)
WO (1) WO2007144323A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094155A1 (en) * 2008-01-22 2009-07-30 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545879B2 (en) 2009-08-31 2013-10-01 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam
WO2019034763A1 (en) 2017-08-17 2019-02-21 Ceva Sante Animale Oral compositions and the preparation methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301304A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
US20020187187A1 (en) * 2001-04-21 2002-12-12 Toshimitsu Ohki Fast disintegrating meloxicam tablet
EP1463488B1 (en) * 2001-12-20 2006-07-19 Alpex Pharma SA Pharmaceutical composition comprising skimmed milk powder
DE10356112A1 (en) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg A pharmaceutical composition of a beta-3 adrenoceptor agonist and a progglandin metabolite
CN1233323C (en) * 2003-12-09 2005-12-28 成都圣诺科技发展有限公司 Orally disintegrating tablet of meloxicam and its preparation
EP1568369A1 (en) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
WO2005117895A2 (en) * 2004-06-04 2005-12-15 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
DE102004033555A1 (en) * 2004-07-09 2006-02-16 Basf Ag Preparation of partial (meth)acrylic esters of dihydric polyalcohols by subjecting specified polyalcohols to esterification with (meth)acrylic acid or to transesterification with (meth)acrylic ester(s) in the presence of enzyme(s)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2009094155A1 (en) * 2008-01-22 2009-07-30 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
US8124603B2 (en) 2008-01-22 2012-02-28 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders

Also Published As

Publication number Publication date
EP2046337B1 (en) 2017-07-19
US10016359B2 (en) 2018-07-10
US20090197874A1 (en) 2009-08-06
EP1870102A1 (en) 2007-12-26
CY1119315T1 (en) 2018-02-14
TW200815015A (en) 2008-04-01
WO2007144323A3 (en) 2008-03-13
EP2046337A2 (en) 2009-04-15
PL2046337T3 (en) 2017-10-31
HUE034161T2 (en) 2018-01-29

Similar Documents

Publication Publication Date Title
US10933090B2 (en) Pharmaceutical compositions
KR100653568B1 (en) Fast Disintegrating Solid Cetirizine Formulations
JP4740740B2 (en) Drug-containing particles and solid preparation containing the particles
US20030161888A1 (en) Pharmaceutical Composition
US10016359B2 (en) Solid forms containing meloxicam with improved buccal taste and process for their preparation
EP2563340A2 (en) Water soluble pharmaceutical composition
JP3119801B2 (en) Method for stabilizing a vitamin-containing composition
WO2012093972A1 (en) Water soluble dosage forms
TW201004625A (en) A fine grain agent having improved water-suspensibility
EP2566449B1 (en) Pharmaceutical compositions comprising ceftibuten
WO2004089343A1 (en) Water soluble tablets
KR20050035907A (en) A composition of fast dissolving tablets containing amlodipine free base
WO2011093831A2 (en) Effervescent formulations comprising cefprozil as active agent
KR100435514B1 (en) Fast dissolving formulation of sildenafil lactate
EA010372B1 (en) Orodispersible pharmaceutical composition of an antithrombolic compound
KR100590696B1 (en) Fast disintegrating granules containing cephalosporin antibiotics and preparation method thereof
WO2004082664A1 (en) Water-soluble tablets of metformin
EP2609911A1 (en) A novel process for preparing orally disintegrating flurbiprofen formulations
KR100307251B1 (en) Dispersible Formulation with Acyclovir Tablet and Its process
EP4561542A1 (en) Orally disintegrating palatable formulations of drotaverine and method of preparation thereof
EP3675832A1 (en) Fast self dispersible dosage forms of deferasirox
JPH09216816A (en) Highly water-soluble and quick-dissolving tablet for pharmaceutical use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07730048

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12299838

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007730048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007730048

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU